OncoMatch/Clinical Trials/NCT07335796
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
Is NCT07335796 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including BMS-986165 and Degarelix for prostate cancer.
Treatment: BMS-986165 · Degarelix — The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage HIGH-RISK LOCALIZED (NCCN)
Excluded: Stage DISTANT (EXTRA-PELVIC) METASTATIC
Documented high-risk localized prostate cancer based on one or more of the following NCCN criteria: 1. PSA ≥ 20ng/ml or 2. Gleason ≥8 or 3. Clinical stage ≥cT3a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: androgen deprivation therapy (GnRH agonists, GnRH antagonists)
Exception: ≤ 4 weeks at time of consent
On ADT (GnRH agonists or antagonists) for > 4 weeks at time of consent
Cannot have received: systemic therapy
Exception: ADT as mentioned in 6.2.2
Other than ADT as mentioned in 6.2.2, prior systemic therapy for treatment of their prostate cancer, including but not limited to chemotherapy, immunotherapy, etc.
Cannot have received: local therapy
Prior local therapy to the prostate for prostate cancer, including but not limited to radiation, HIFU, phototherapy, etc.
Lab requirements
Blood counts
ANC ≥ 1.5 K/mcL; Hemoglobin ≥ 9g/dL; Platelet count ≥ 100 K/mcL
Kidney function
CrCl > 60 mL/min (Cockcroft-Gault or 24-hour urine collection)
Liver function
Total Bilirubin ≤ 1.5 x ULN (Gilbert's syndrome exception: direct bilirubin ≤1.5 × ULN); SGOT (AST) ≤ 2.5 x ULN; SGPT (ALT) ≤ 2.5 x ULN
Cardiac function
LVEF ≥ 50%; no complete left bundle branch, high-grade AV block, or other significant ECG abnormality; no history of significant bradycardia, QTcF ≥ 450 ms, sustained ventricular arrhythmia, long QT syndrome, cardiomyopathy, CHF (NYHA III/IV ≤ 12 months), MI/myocarditis/pericarditis ≤ 6 months, unstable angina, poorly controlled hypertension (systolic ≥ 160 mmHg or diastolic ≥ 95 mmHg)
Normal organ function with acceptable initial laboratory values within 28 days of registration: ANC ≥ 1.5 K/mcL Hemoglobin ≥ 9g/dL Platelet count ≥ 100 K/mcL Potassium* within institutional normal range Calcium* within institutional normal range Magnesium* within institutional normal range Total Bilirubin ≤ 1.5 x ULN (Note: In participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin is ≤1.5 × ULN, participant may be eligible) SGOT (AST) ≤ 2.5 x ULN SGPT (ALT) ≤ 2.5 x ULN CrCl** > 60 mL/min *If these electrolytes are corrected with supplements, eligibility should be confirmed prior to the first dose of study intervention. **Using Cockcroft-Gault equation or measured CrCl using 24-hour urine collection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify